title: How should "RET positive" NSCLC be treated?
authors.affiliation: Dept. Thoracic Oncology, Netherlands Cancer Institute & Dept. Pulmonary Diseases, Vrije Universiteit VU Medical Center, Amsterdam, The Netherlands. Electronic address: e.smit@nki.nl.
authors.forename: Egbert F
authors.initials: EF
authors.lastname: Smit
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000235:genetics* / Q000378:metabolism; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000235:genetics* / Q000378:metabolism; D058990:Molecular Targeted Therapy; D047428:Protein Kinase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D051096:Proto-Oncogene Proteins c-ret / Q000037:antagonists & inhibitors / Q000235:genetics*; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D051096:Proto-Oncogene Proteins c-ret